Federal Register #2026-16443

NCI Seeks Partners for Oncology Diagnostics, Therapeutics, and Imaging Technologies

This opportunity from the National Cancer Institute (NCI), Technology Transfer Center, seeks licensing and co-development partners for three innovative oncology technologies: - Government Buyer: - National Cancer Institute (NCI), Technology Transfer Center - Technologies Available for Licensing/Co-Development: - DNA Methylation-Based Classifier for CNS and Kidney Tumors - Software-enabled solution using DNA methylation patterns for improved diagnosis and subtyping - Developed from over 16,000 methylation profiles - Part number: E10520230 - Monoclonal Antibody RO4 for Mesothelin-Expressing Cancers - Novel antibody targeting the juxta-membrane region of mesothelin (MSLN) - Blocks mesothelin shedding, enhancing therapeutic engagement - Applications include mesothelioma, ovarian, and pancreatic cancers - Demonstrates higher binding affinity and cytotoxicity than previous antibodies - Part number: E0512024 - Quantitative Particle Identification (QPID) Digital Autoradiography System - Prototype device using Timepix3 detector technology - Measures individual radioactive decay events for improved autoradiography imaging and radiotherapy guidance - Part number: E2012023 - Notable Requirements and Details: - NCI is seeking partners for licensing and/or co-development - Technologies are at prototype or pre-clinical stages - Intended for commercial applications in oncology diagnostics, therapeutics, and research - No commercial OEMs are mentioned; all technologies are developed by NCI.

Description

The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a novel monoclonal antibody (mAb), RO4, that can be used to treat mesothelin (MSLN) expressing cancers. This antibody specifically binds to the juxta-membrane region of MSLN to block shedding, enhancing therapeutic engagement at the cell surface. RO4 demonstrates higher binding affinity and cytotoxicity compared to previous antibodies and shows broader binding across MSLN-positive cell types. The NCI is interested in licensing and co-development collaborations to further develop RO4 for treating MSLN-positive cancers.

View original listing